Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRBU Caribou Biosciences	$1.26 -6.7%	$1.03	$0.66 ▼ $3.00	$117.18M	2.44	1.33 million shs	12.13 million shs
FATE Fate Therapeutics	$1.04 -5.5%	$1.23	$0.66 ▼ $5.92	$119.18M	2.23	2.21 million shs	3.75 million shs
HBPCF Helix Biopharma	$0.60	$0.59	$0.59 ▼ $0.60	$31.81M	-0.15	1 shs	N/A
NKTX Nkarta	$1.66 -4.0%	$1.87	$1.31 ▼ $8.23	$117.79M	0.72	1.03 million shs	625,328 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRBU Caribou Biosciences	0.00%	-5.97%	+17.21%	+37.99%	-23.17%
FATE Fate Therapeutics	0.00%	-12.61%	-15.79%	+31.63%	-68.29%
HBPCF Helix Biopharma	0.00%	0.00%	0.00%	+31.90%	+335.73%
NKTX Nkarta	0.00%	-6.21%	-5.41%	-9.78%	-71.91%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRBU Caribou Biosciences	2.0568 of 5 stars	3.5	1.0	0.0	0.0	2.2	1.7	0.6
FATE Fate Therapeutics	4.1328 of 5 stars	3.1	3.0	0.0	4.7	2.5	1.7	0.6
HBPCF Helix Biopharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NKTX Nkarta	2.2222 of 5 stars	3.6	1.0	0.0	0.0	2.6	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRBU Caribou Biosciences	3.00	Buy	$8.50	574.60% Upside
FATE Fate Therapeutics	2.13	Hold	$3.83	268.59% Upside
HBPCF Helix Biopharma	0.00	N/A	N/A	N/A
NKTX Nkarta	3.13	Buy	$14.33	763.45% Upside

Current Analyst Ratings Breakdown

Latest HBPCF, FATE, CRBU, and NKTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/12/2025	FATE Fate Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
6/10/2025	NKTX Nkarta	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$16.00 ➝ $14.00
5/15/2025	NKTX Nkarta	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform
5/15/2025	NKTX Nkarta	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$11.00 ➝ $10.00
5/14/2025	FATE Fate Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$10.00 ➝ $2.00
5/14/2025	FATE Fate Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$5.00 ➝ $4.00
5/14/2025	FATE Fate Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
4/28/2025	CRBU Caribou Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $3.00
4/9/2025	NKTX Nkarta	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$11.00 ➝ $11.00

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRBU Caribou Biosciences	$9.99M	11.73	N/A	N/A	$2.79 per share	0.45
FATE Fate Therapeutics	$13.63M	8.74	N/A	N/A	$2.80 per share	0.37
HBPCF Helix Biopharma	N/A	N/A	N/A	N/A	N/A	N/A
NKTX Nkarta	N/A	N/A	N/A	N/A	$5.78 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRBU Caribou Biosciences	-$149.10M	-$1.62	N/A	N/A	N/A	-1,490.84%	-55.70%	-45.35%	8/5/2025 (Estimated)
FATE Fate Therapeutics	-$186.26M	-$1.49	N/A	N/A	N/A	-1,318.93%	-47.17%	-34.60%	8/12/2025 (Estimated)
HBPCF Helix Biopharma	-$6.82M	-$0.14	N/A	∞	N/A	N/A	N/A	-694.39%	N/A
NKTX Nkarta	-$108.79M	-$1.51	N/A	N/A	N/A	N/A	-26.64%	-21.62%	8/12/2025 (Estimated)

Latest HBPCF, FATE, CRBU, and NKTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
6/16/2025	Q3 2025	HBPCF Helix Biopharma	N/A	-$0.02	N/A	-$0.02	N/A	N/A
5/14/2025	Q1 2025	NKTX Nkarta	-$0.44	-$0.43	+$0.01	-$0.43	N/A	N/A
5/13/2025	Q1 2025	FATE Fate Therapeutics	-$0.39	-$0.32	+$0.07	-$0.32	$1.18 million	$1.63 million
5/8/2025	Q1 2025	CRBU Caribou Biosciences	-$0.43	-$0.43	N/A	-$0.43	$1.48 million	$2.35 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRBU Caribou Biosciences	N/A	N/A	N/A	N/A	N/A
FATE Fate Therapeutics	N/A	N/A	N/A	N/A	N/A
HBPCF Helix Biopharma	N/A	N/A	N/A	N/A	N/A
NKTX Nkarta	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRBU Caribou Biosciences	N/A	7.63	7.63
FATE Fate Therapeutics	N/A	8.81	8.81
HBPCF Helix Biopharma	N/A	0.99	0.99
NKTX Nkarta	N/A	14.48	14.48

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRBU Caribou Biosciences	77.51%
FATE Fate Therapeutics	97.54%
HBPCF Helix Biopharma	N/A
NKTX Nkarta	80.54%

Insider Ownership

Company	Insider Ownership
CRBU Caribou Biosciences	9.50%
FATE Fate Therapeutics	5.51%
HBPCF Helix Biopharma	7.60%
NKTX Nkarta	8.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRBU Caribou Biosciences	100	93.00 million	84.17 million	Optionable
FATE Fate Therapeutics	550	114.60 million	108.29 million	Optionable
HBPCF Helix Biopharma	9	53.02 million	48.99 million	Not Optionable
NKTX Nkarta	140	70.96 million	65.00 million	Optionable

HBPCF, FATE, CRBU, and NKTX Headlines

Recent News About These Companies

Will Nkarta (NASDAQ:NKTX) Spend Its Cash Wisely?

June 27 at 4:32 PM | uk.finance.yahoo.com

Nkarta, Inc. (NKTX) - Yahoo Finance

June 24, 2025 | finance.yahoo.com

Nkarta (NASDAQ:NKTX) Given New $14.00 Price Target at Mizuho

June 10, 2025 | marketbeat.com

Nkarta, Inc. (NASDAQ:NKTX) Receives Consensus Recommendation of "Buy" from Analysts

June 10, 2025 | marketbeat.com

Bank of America Corp DE Grows Stock Holdings in Nkarta, Inc. (NASDAQ:NKTX)

June 8, 2025 | marketbeat.com

Nkarta CMO David Shook Steps Down, Shawn Rose To Succeed

June 7, 2025 | nasdaq.com

Nkarta, Inc.: Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus

June 6, 2025 | finanznachrichten.de

Nkarta, Inc. Appoints Dr. Shawn Rose as Chief Medical Officer and Head of R&D

June 6, 2025 | quiverquant.comQ

Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus

June 6, 2025 | globenewswire.com

Millennium Management LLC Boosts Position in Nkarta, Inc. (NASDAQ:NKTX)

June 4, 2025 | marketbeat.com

Nkarta (NKTX) Moves to Buy: Rationale Behind the Upgrade

May 19, 2025 | zacks.com

Nkarta Downgraded, Analyst Cites Competitive Pressure In Autoimmune Space

May 15, 2025 | benzinga.com

William Blair Downgrades Nkarta (NKTX)

May 15, 2025 | msn.com

Nkarta, Inc.: Nkarta Reports First Quarter 2025 Financial Results and Corporate Highlights

May 15, 2025 | finanznachrichten.de

Nkarta Reports First Quarter 2025 Financial Results and Corporate Highlights

May 14, 2025 | globenewswire.com

Nkarta (NKTX) Upgraded to Buy: Here's Why

April 14, 2025 | zacks.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Phathom Pharmaceuticals (PHAT), Nkarta (NKTX) and Regeneron (REGN)

April 9, 2025 | markets.businessinsider.com

Nkarta to Participate in an April Investor Conference

April 1, 2025 | globenewswire.com

Nkarta: Betting On The Turnaround

March 31, 2025 | seekingalpha.com

Nkarta: Betting On The Turnaround

March 31, 2025 | seekingalpha.com

Nkarta: Grinding Lower, Trying To Find Support

March 31, 2025 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Intel's Turnaround Strategy Shifts From Planning to Attack Mode
By Jeffrey Neal Johnson | June 20, 2025
View Intel's Turnaround Strategy Shifts From Planning to Attack Mode
3 Semiconductor Stocks Poised to Surge on AI Spending
By Chris Markoch | June 25, 2025
View 3 Semiconductor Stocks Poised to Surge on AI Spending
In a Historic Shift, 2 Cybersecurity Stocks Plan to Buyback Stock
By Leo Miller | June 9, 2025
View In a Historic Shift, 2 Cybersecurity Stocks Plan to Buyback Stock

HBPCF, FATE, CRBU, and NKTX Company Descriptions

Caribou Biosciences NASDAQ:CRBU

$1.26 -0.09 (-6.67%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$1.21 -0.05 (-3.97%)

As of 04:03 AM Eastern

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.

Fate Therapeutics NASDAQ:FATE

$1.04 -0.06 (-5.45%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$1.08 +0.04 (+3.85%)

As of 04:04 AM Eastern

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Helix Biopharma OTCMKTS:HBPCF

$0.60 0.00 (0.00%)

As of 06/27/2025

Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging. The company is headquartered in Toronto, Canada.

Nkarta NASDAQ:NKTX

$1.66 -0.07 (-4.05%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$1.71 +0.05 (+3.01%)

As of 05:19 AM Eastern

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time